User:Jackdrey1/Silvia Caballero
SIlvia Caballero | |
|---|---|
| Nationality | Latin American |
| Alma mater | Bachelors in biological sciences from Hunter College, Doctorate in microbiology and immunology from Weill Cornell Medical College |
| Scientific career | |
| Fields | Biological Scientist |
| Institutions | Memorial Sloan-Kettering Cancer Center, Vedanta Biosciences |
 | This is the sandbox page where you will draft your initial Wikipedia contribution.
If you're starting a new article, you can develop it here until it's ready to go live. If you're working on improvements to an existing article, copy only one section at a time of the article to this sandbox to work on, and be sure to use an edit summary linking to the article you copied from. Do not copy over the entire article. You can find additional instructions here. Remember to save your work regularly using the "Publish page" button. (It just means 'save'; it will still be in the sandbox.) You can add bold formatting to your additions to differentiate them from existing content. |
Silvia Caballero is a Peruvian microbiologist, heading the multidrug-resistant organism, or MDRO, decolonization program at the biopharmaceutical company Vedanta Biosciences in Cambridge, Massachusetts.[1]
Education and early career
[edit]Silvia Caballero received her bachelor degree in biological sciences from Hunter College.[1] From there she attended graduate school at Weill Cornell Medical College where she obtained her doctorate degree in microbiology and immunology.[1] While attending Weill, she conducted research at Memorial Sloan-Kettering Cancer Center, where she discovered MDROs that eliminate the gut bacteria responsible for fighting off infections.[2] Resistant bacteria was discovered by Silvia through a series of experiments conducted with mice, that’s guts had been altered to resemble our own.[2][3][4]
Career and awards
[edit]After the completion of her doctorate, Silvia's research continued when she was hired as the Director of Infectious Diseases at Vedanta Biosciences.[3] [5] As the Director of Infectious Diseases,[5] it's Silvia's goal to mass produce her own drug in the United States to help those that cannot fight of MDROs on their own.[2][3][4] Three specified bacteria have been isolated targets for Silvia,[2] with human trials using a combination of natural bacteria that can defend against MDROs is her and her teams next step, predicted to start back in 2021.[3][2]
Silvia's achievements granted her the award of Innovators Under 35 Latin America in 2018 from Massachusetts Institute of Technology,[3] along with making the TIME 100 NEXT in 2019.[4] Both recognizing her for the achievements in increasing our understanding of, their identification, and future protection from MDROs.[3][4]
References
[edit]- ^ a b c "Vedanta Biosciences' Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35 :". Vedanta Biosciences, Inc. 2019-06-25. Retrieved 2023-07-02.
- ^ a b c d e "Silvia Caballero". MIT Technology Review. Retrieved 2023-07-02.
- ^ a b c d e f "Silvia Caballero | Innovators Under 35". www.innovatorsunder35.com. Retrieved 2023-07-02.
- ^ a b c d "TIME 100 Next 2019: Silvia Caballero". Time. Retrieved 2023-06-28.
- ^ a b "Team :". Vedanta Biosciences, Inc. Retrieved 2023-07-02.